Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer

[1]  Y. Ishikawa,et al.  Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer , 2018, Gastric Cancer.

[2]  H. Doyama,et al.  Phase II study of S-1 plus oxaliplatin 130 mg/m2 in Japanese patients with advanced gastric cancer , 2018, International Journal of Clinical Oncology.

[3]  Y. Ishikawa,et al.  Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer , 2018, Journal of Gastroenterology.

[4]  Masato Nakamura,et al.  Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06) , 2017, Gastric Cancer.

[5]  Soo-Jeong Cho,et al.  A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer. , 2017, European journal of cancer.

[6]  T. Sano.  Gastric cancer: Asia and the world , 2017, Gastric Cancer.

[7]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2014 (ver. 4) , 2016, Gastric Cancer.

[8]  Yoon-Koo Kang,et al.  Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. , 2015, European journal of cancer.

[9]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[10]  L. Shen,et al.  Erratum to: Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy , 2015, Journal of Gastroenterology.

[11]  H. Imamura,et al.  Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. , 2015 .

[12]  Y. Doki,et al.  Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1) , 2014, British Journal of Cancer.

[13]  Kazuhiro Yoshida,et al.  Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. , 2013, The Lancet. Oncology.

[14]  Inkyung Jung,et al.  A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. , 2012, European journal of cancer.

[15]  E. Baba,et al.  Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study , 2011, Gastric Cancer.

[16]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[17]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[18]  C. Tournigand,et al.  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Baba,et al.  Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Jun Yu Li,et al.  Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  N. Sugimoto,et al.  Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G) , 2017, Gastric Cancer.

[22]  L. Shen,et al.  Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy , 2015, Journal of Gastroenterology.